Improvement of systemic 5-aminolevulinic acid-based photodynamic therapy in vivo using light fractionation with a 75-minute interval.

We have studied different single and fractionated illumination schemes after systemic administration of 5-aminolevulinic acid (ALA) to Improve the response of nodular tumors to ALA-mediated photodynamic therapy. Tumors transplanted on the thigh of female WAG/Rij rats were transdermally illuminated with red light (633 nm) after systemic ALA administration (200 mg/kg). The effectiveness of each treatment scheme was determined from the tumor volume doubling time. A single illumination (100 J/cm2 at 100 mW/cm2, 2.5 h after ALA administration) yielded a doubling time of 6.6+/-1.2 days. This was significantly different from the untreated control (doubling time, 1.7+/-0.1 days). The only treatment scheme that yielded a significant improvement compared to all other schemes studied was illumination at both 1 and 2.5 h after ALA administration (both 100 J/cm2 at 100 mW/cm2) and resulted in a tumor volume doubling time of 18.9+/-2.9 days. A possible mechanism to explain this phenomenon is that the protoporphyrin IX formed after administration of ALA is photodegraded by the first illumination. In the 75-min interval, new porphyrin is formed enhancing the effect of the second illumination.

[1]  Thomas J. Flotte,et al.  Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment , 2004, Archives of Dermatological Research.

[2]  T. Foster,et al.  Effectiveness of delta-aminolevulinic acid-induced protoporphyrin as a photosensitizer for photodynamic therapy in vivo. , 1995, Cancer research.

[3]  H. Tideman Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity , 1999 .

[4]  H. S. de Bruijn,et al.  Photobleaching during and re‐appearance after photodynamic therapy of topical ALA‐induced fluorescence in UVB‐treated mouse skin , 1997, International journal of cancer.

[5]  J Moan,et al.  5‐Aminolevulinic acid‐based photodynamic therapy , 1997, Cancer.

[6]  P. Calzavara-Pinton,et al.  Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. , 1995, Journal of photochemistry and photobiology. B, Biology.

[7]  Stanley B. Brown,et al.  Fluorescence Photobleaching of ALA‐induced Protoporphyrin IX during Photodynamic Therapy of Normal Hairless Mouse Skin: The Effect of Light Dose and Irradiance and the Resulting Biological Effect , 1998, Photochemistry and photobiology.

[8]  G. Buonaccorsi,et al.  Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. , 1995, British Journal of Cancer.

[9]  J Moan,et al.  DISTRIBUTION OF 5‐AMINOLEVULINIC ACID‐INDUCED PORPHYRINS IN NODULOULCERATIVE BASAL CELL CARCINOMA , 1995, Photochemistry and photobiology.

[10]  T. Hasan,et al.  A theoretical study of light fractionation and dose-rate effects in photodynamic therapy. , 1997, Radiation research.

[11]  W. Star,et al.  In vivo fluorescence kinetics and photodynamic therapy using 5-aminolaevulinic acid-induced porphyrin: increased damage after multiple irradiations. , 1994, British Journal of Cancer.

[12]  J C Kennedy,et al.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. , 1992, Journal of photochemistry and photobiology. B, Biology.

[13]  H. Barr,et al.  Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX , 1996, The Lancet.